This post is sponsored by DIA.
This vital question for the future of health care worldwide will be asked during the premier life sciences meeting in North America, the DIA 2013 49th Annual Meeting.
DIA 2013 49th Annual Meeting will be held in Boston, Mass. from June 23-27, and will feature a session titled “Defining Clinical Trial Innovation: Challenges and Opportunities for 2013” under the Communities Showcase track. The forum, developed by the DIA’s Clinical Research Community, will give participants the chance to discuss the challenges and opportunities for innovation to improve global health and fulfill unmet medical needs.
Panelists will give their views on whether the regulated and increasingly resource-constrained R&D environment will have opportunities for innovation to ensure a sustainable future. The panelists will include Craig H. Lipset, Head of Clinical Innovation, Worldwide Research and Development, Pfizer Inc; Andreas Koester, MD, PhD, Vice President, Clinical Trial Innovation, External Alliances, Janssen Pharmaceutical Companies of J&J; and Jeffrey S. Kasher, PhD, Vice President, Global Clinical Development, Eli Lilly and Company.
The session will be chaired by Susan K. Nunchuck, PhD, MSN, Senior Clinical Research Associate, Actelion Clinical Research.
Participants in the session, to be held on June 24 from 2:30 to 4:00 p.m., will learn to define clinical trial innovation in 2013; identify key challenges and opportunities for innovation in clinical trials; and define funding resources in a constrained, highly regulated environment.
The DIA 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science is the largest multidisciplinary event that brings together a global community of life sciences professionals at all levels and across all disciplines in the discovery, development, and life cycle management of medical products, all with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies for patients.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Returning to Boston, one of the strongest life sciences regions in the United States, this year’s program will feature 250+ educational offerings over 22 tracks on hot topics from key thought leaders from the life sciences industry.
The DIA Annual Meeting provides participants with a valuable opportunity to meet professionals from around the world, share knowledge and experience, network, and build new relationships.
Find out more about DIA 2013 49th Annual Meeting at www.diahome.org/DIA2013.
Register by May 17 to reserve your spot on the Advance Attendee List.
